Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy

Tuberculosis (TB) is top infectious disease killer caused by a single organism responsible for 1.5 million deaths in 2018. Both COVID-19 and the pandemic response are risking to affect control measures for TB and continuity of essential services for people affected by this infection in western count...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Infection Ročník 49; číslo 5; s. 1061 - 1064
Hlavní autoři: Musso, Maria, Di Gennaro, Francesco, Gualano, Gina, Mosti, Silvia, Cerva, Carlotta, Fard, Saeid Najafi, Libertone, Raffaella, Di Bari, Virginia, Cristofaro, Massimo, Tonnarini, Roberto, Castilletti, Concetta, Goletti, Delia, Palmieri, Fabrizio
Médium: Journal Article
Jazyk:angličtina
Vydáno: Berlin/Heidelberg Springer Berlin Heidelberg 01.10.2021
Springer Nature B.V
Témata:
Anergy
Bacterial diseases
Case Report
Coronaviruses
COVID-19
Developing countries
Differential diagnosis
Family Medicine
General Practice
Immune system
Immunology
Infectious Diseases
Internal Medicine
LDCs
Medicine
Medicine & Public Health
Pandemics
Patients
Pneumonia
Respiratory failure
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Tuberculosis
Viral diseases
COVID-19
SARS-CoV-2
Tuberculosis
IGRA test
ISSN:0300-8126, 1439-0973, 1439-0973
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Tuberculosis (TB) is top infectious disease killer caused by a single organism responsible for 1.5 million deaths in 2018. Both COVID-19 and the pandemic response are risking to affect control measures for TB and continuity of essential services for people affected by this infection in western countries and even more in developing countries. Knowledge about concomitant pulmonary TB and COVID-19 is extremely limited. The double burden of these two diseases can have devastating effects. Here, we describe from both the clinical and the immunological point of view a case of a patient with in vitro immune cell anergy affected by bilateral cavitary pulmonary TB and subsequent COVID-19-associated pneumonia with a worst outcome. COVID-19 can be a precipitating factor in TB respiratory failure and, during ongoing SARS-COV-2 pandemic, clinicians must be aware of this possible co-infection in differential diagnosis of patients with active TB and new or worsening chest imaging.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0300-8126
1439-0973
1439-0973
DOI:10.1007/s15010-021-01576-y